A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC

Summary

To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in the treatment of patients with severe clinical and laboratory manifestations of HIV infection. To compare the safety and tolerance of AZT administered 2, 3, and 6 x daily to these patients.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications